The objective of the study is to assess weight and metabolic effects of 6 months of treatment with second-generation antipsychotics in naïve/quasi-naïve youths.

This study looked at a non-randomized, naturalistic, multicenter, inception cohort study including 279 patients aged 4-17 (mean=14.6±2.9) years. Of those, 248 (88.8%) received a single antipsychotic (risperidone, olanzapine or quetiapine) and completed 2 visits, and 178 (63.8%) completed the 6-month follow-up. Patients had schizophrenia-spectrum disorders (44.5%), mood-spectrum disorders (23.2%), disruptive behavioral disorders (17.3%), or other disorders (15.1%). Fifteen age-/gender-matched, healthy, non-medicated individuals served as a comparison group.

READ FULL ARTICLE Curated publisher From www.jaacap.com